信立泰拟赴港二次上市：董事长叶宇翔年薪127万元，82岁父亲任董事

Core Viewpoint - The company, Sinopharm (信立泰), is planning to issue overseas shares (H shares) and list on the Hong Kong Stock Exchange to advance its global strategy and support high-quality development [2] Group 1: Company Overview - Sinopharm was established in 1998 and went public in 2009, focusing on the research, production, and sales of pharmaceuticals and medical devices, as well as patent licensing [2] - The company's main products include cardiovascular drugs and medical devices, cephalosporin antibiotics, and orthopedic drugs, with ongoing projects in various therapeutic areas such as cardiovascular, metabolism, autoimmune, nephrology, orthopedics, and oncology [2] Group 2: Financial Performance - The operating revenue for Sinopharm was 3.482 billion yuan in 2022, 3.365 billion yuan in 2023, and is projected to be 4.012 billion yuan in 2024 [2] - The net profit attributable to shareholders was 637 million yuan in 2022, 580 million yuan in 2023, and is expected to be 602 million yuan in 2024 [2] - For the first three quarters of 2025, the operating revenue was 3.241 billion yuan, representing an 8% year-on-year increase, while the net profit attributable to shareholders was 581 million yuan, reflecting a 13.93% year-on-year growth [2] Group 3: Shareholder Information - The actual controllers of Sinopharm are Ye Chenghai, Liao Qingqing, Ye Yuxuan, Chen Zhiming, and Ye Yuxun [3][4] - Ye Yuxuan serves as the chairman of the company, while Ye Chenghai holds the position of non-independent director [5][6]